Full Press Release Details
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union.
BIIB
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
Key Takeaway: FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis